Side Effects of vibegron: A Synthesis of Findings from 7 Studies

  1. Home
  2. Side Effects of vibegron
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of vibegron: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of vibegron: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Vibegron is a new β3-adrenergic receptor agonist for the treatment of overactive bladder (OAB). Compared to traditional anticholinergics, vibegron has shown efficacy in improving OAB symptoms with fewer side effects, making it a potentially valuable alternative for patients who are intolerant to or experience undesirable effects from anticholinergics. 6 This is particularly relevant for patients with anticholinergic-resistant OAB, as seen in a case report where vibegron successfully treated a pediatric patient with neurogenic detrusor overactivity. 5

Reasons for Side Effects

Vibegron works by relaxing the muscles of the bladder through its action on the β3-adrenergic receptors. This mechanism aims to reduce urinary urgency and frequency. However, these receptors are also found in other organs, making it possible for vibegron to affect those areas as well. 1 This potential for wider organ impact can contribute to the occurrence of side effects.

Common Side Effects

Urinary Retention

The most prevalent side effect associated with vibegron is urinary retention. 1 Due to the bladder muscle relaxation, urination may become challenging. This risk is particularly elevated in men with pre-existing urinary conditions such as benign prostatic hypertrophy. 1

Side Effect Management

Urinary Retention

In cases of urinary retention, it's essential to discontinue vibegron use and consult a physician. 1

Comparison Across Studies

Commonalities

Several studies have consistently demonstrated that vibegron effectively improves OAB symptoms. 6 , 5 , 4 , 3 , 2 , 1 Additionally, the research consistently highlights the advantage of vibegron over traditional anticholinergics in terms of fewer side effects. 6 , 2

Differences

Variations exist in the reported frequency and severity of side effects associated with vibegron across different studies. 1 For instance, the occurrence of urinary retention due to vibegron has been documented with varying rates. 1 These discrepancies are likely attributable to factors such as study design and participant characteristics. 1

Considerations for Real-World Application

While vibegron holds promise as a treatment for OAB, it's crucial to remember the potential for side effects. 1 Individuals with pre-existing urinary issues, particularly men with benign prostatic hypertrophy, are at a higher risk for urinary retention. 1 It's essential to consult a doctor before starting vibegron to ensure it aligns with your individual health profile and conditions. 1

Limitations of Current Research

The research on vibegron remains limited in scope. 1 Further investigation is necessary to comprehensively assess its long-term safety and effectiveness. 1

Future Research Directions

Research should focus on evaluating the long-term safety and efficacy of vibegron. 1 Additionally, studies are needed to provide more detailed information about the types and frequency of side effects associated with vibegron. 1

Conclusion

Vibegron offers potential benefits for OAB treatment, but it's important to be aware of potential side effects. 1 It's crucial to consult your physician before starting vibegron to determine if it's the right choice for you based on your health history and current conditions. 1

Literature analysis of 7 papers
Positive Content
6
Neutral Content
1
Negative Content
0
Article Type
0
0
0
0
7
4.

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.

Author: ChenJing Voon, GahnJames C, NesheimJeffrey, MuddPaul N

Improved OAB treatment
Reduced OAB burden
Dementia risk
Fall risk

This analysis assessed the budget impact of introducing the β<sub>3</sub>-adrenergic agonist vibegron for the treatment of overactive bladder (OAB) in the US from commercial payor and Medicare perspectives.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.

Author: KatoTaiki, MizunoKentaro, NishioHidenori, YasuiTakahiro, HayashiYutaro

NDO treatment

This case report describes the use of vibegron, a selective beta-3 adrenoreceptor agonist, to treat anticholinergic-resistant neurogenic detrusor overactivity (NDO) in a young girl with tethered cord syndrome following myelomeningocele repair.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Author: MitchesonHenry D, SamantaSuvajit, MuldowneyKaren, PintoCathy A, RochaBeatriz de A, GreenStuart, BennettNathan, MuddPaul N, FrenklTara L

OAB symptom improvement
tolerability
short duration

Once-daily vibegron 50 and 100 mg improved overactive bladder (OAB) symptoms and was well tolerated alone or with tolterodine.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.